CompletedPhase 2NCT01104025
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
Studying Acquired hemophagocytic lymphohistiocytosis associated with malignant disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Hospital Medical Center, Cincinnati
- Principal Investigator
- Michael Jordan, MDChildren's Hospital Medical Center, Cincinnati
- Intervention
- ATG, rabbit(drug)
- Enrollment
- 31 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2010 – 2016
Study locations (15)
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- University of California, San Francisco Department of Pediatrics, San Francisco, California, United States
- Stanford University, Stanford, California, United States
- University of Colorado, Aurora, Colorado, United States
- Nemours, Wilmington, Delaware, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Nemours, Jacksonville, Florida, United States
- Florida All Children's Hospital, St. Petersburg, Florida, United States
- Tulane University Medical Center, New Orleans, Louisiana, United States
- Children's Hospital Boston, Boston, Massachusetts, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Oregon Health and Science University, Portland, Oregon, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Texas Children's Cancer Center/Baylor College of Medicine, Houston, Texas, United States
- The Hospital for Sick Children, Toronto, Ontario, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01104025 on ClinicalTrials.govOther trials for Acquired hemophagocytic lymphohistiocytosis associated with malignant disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07525466Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)Beijing Tongren Hospital
- RECRUITINGPHASE4NCT07270835Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell LymphomaThe First Affiliated Hospital of Soochow University
- RECRUITINGNANCT07488728Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic LymphohistiocytosisBeijing Children's Hospital
- RECRUITINGPHASE2NCT06160791Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)Jerry Lee, MD, MSc, MPhil
- ACTIVE NOT RECRUITINGNCT06587191Emapalumab Efficacy in Children With Primary Hemophagocytic LymphohistiocytosisFederal Research Institute of Pediatric Hematology, Oncology and Immunology
- RECRUITINGNCT06339177Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE StudyNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGNCT06614998Establishment of an Early Warning Screening System for Hemophagocytic Lymphohistiocytosis a Multi-center, Prospective StudyThe Affiliated Hospital of Xuzhou Medical University
- RECRUITINGNCT06585124Flow Cytometry for the Study of T-Cell Populations in Hemophagocytic Lymphohistiocytosis Associated With LymphomasFondazione Policlinico Universitario Agostino Gemelli IRCCS
See all trials for Acquired hemophagocytic lymphohistiocytosis associated with malignant disease →